This work is licensed under the Creative Commons Attribution 4.0 International License.
Logan C, Martin-Loeches I, Bicanic T. Invasive candidiasis in critical care: challenges and future directions. Intensive Care Med 2020;46(11):2001-14.LoganCMartin-LoechesIBicanicTInvasive candidiasis in critical care: challenges and future directionsIntensive Care Med2020461120011410.1007/s00134-020-06240-x32990778Search in Google Scholar
Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff M, et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med 2014;40(9):1303-12.LortholaryORenaudatCSitbonKMadecYDenoeud-NdamLWolffMet alWorrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010)Intensive Care Med201440913031210.1007/s00134-014-3408-3414724725097069Search in Google Scholar
Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62(4):e1-50.PappasPGKauffmanCAAndesDRClancyCJMarrKAOstrosky-ZeichnerLet alClinical practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of AmericaClin Infect Dis2016624e15010.1093/cid/civ933472538526679628Search in Google Scholar
Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012;18(Suppl 7):19-37.CornelyOABassettiMCalandraTGarbinoJKullbergBJLortholaryOet alESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patientsClin Microbiol Infect201218Suppl 7193710.1111/1469-0691.1203923137135Search in Google Scholar
Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009;37(5):1612-8.LeroyOGangneuxJPMontraversPMiraJPGouinFSolletJPet alEpidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006)Crit Care Med20093751612810.1097/CCM.0b013e31819efac019325476Search in Google Scholar
Thomas-Rüddel DO, Schlattmann P, Pletz M, Kurzai O, Bloos F. Risk Factors for Invasive Candida Infection in Critically Ill Patients: A Systematic Review and Meta-analysis. Chest 2022;161(2):345-55.Thomas-RüddelDOSchlattmannPPletzMKurzaiOBloosFRisk Factors for Invasive Candida Infection in Critically Ill Patients: A Systematic Review and Meta-analysisChest202216123455510.1016/j.chest.2021.08.081894162234673022Search in Google Scholar
Bruyère R, Quenot JP, Prin S, Dalle F, Vigneron C, Aho S, et al. Empirical antifungal therapy with an echinocandin in criticallyill patients: prospective evaluation of a pragmatic Candida score-based strategy in one medical ICU. BMC Infect Dis 2014;14:385.BruyèreRQuenotJPPrinSDalleFVigneronCAhoSet alEmpirical antifungal therapy with an echinocandin in criticallyill patients: prospective evaluation of a pragmatic Candida score-based strategy in one medical ICUBMC Infect Dis20141438510.1186/1471-2334-14-385422729625015848Search in Google Scholar
Ciurea CN, Santini A, Mare AD, Kosovski IB, Toma F, Vintila C, Pintea-Simon IA, Man A. Candida Spp. in Lower Respiratory Tract Secretions - A Ten Years Retrospective Study. J Crit Care Med (Targu Mures) 2021;7(3):217-26.CiureaCNSantiniAMareADKosovskiIBTomaFVintilaCPintea-SimonIAManACandida Sppin Lower Respiratory Tract Secretions - A Ten Years Retrospective Study. J Crit Care Med (Targu Mures)2021732172610.2478/jccm-2021-0016851938334722925Search in Google Scholar
Cui N, Wang H, Su L, Qiu H, Li R, Liu D, et al. Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study. BMC Infect Dis 2017;17(1):93.CuiNWangHSuLQiuHLiRLiuDet alInitial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN studyBMC Infect Dis20171719310.1186/s12879-017-2207-1526013328114898Search in Google Scholar
Nucci M, Nouér SA, Esteves P, Guimarães T, Breda G, de Miranda BG, et al. Discontinuation of empirical antifungal therapy in ICU patients using 1,3-β-d-glucan. J Antimicrob Chemother 2016;71:2628-33.NucciMNouérSAEstevesPGuimarãesTBredaGde MirandaBGet alDiscontinuation of empirical antifungal therapy in ICU patients using 1,3-β-d-glucanJ Antimicrob Chemother20167126283310.1093/jac/dkw18827287231Search in Google Scholar
Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-5.MorrellMFraserVJKollefMHDelaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortalityAntimicrob Agents Chemother2005493640510.1128/AAC.49.9.3640-3645.2005Search in Google Scholar
Hsu DI, Nguyen M, Nguyen L, Law A, Wong-Beringer A. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J Antimicrob Chemother 2010;65:1765-70.HsuDINguyenMNguyenLLawAWong-BeringerAA multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patientsJ Antimicrob Chemother20106517657010.1093/jac/dkq216Search in Google Scholar
Falces-Romero I, Romero-Gómez MP, Moreno-Ramos F, Mingorance J, García-Rodríguez J, Cendejas-Bueno E. Epidemiology of bloodstream Candida species in a Spanish tertiary care hospital as a guide for implementation of T2MR (T2CANDIDA®) for rapid diagnosis of candidemia. Med Mycol 2021;59(4):350-4.Falces-RomeroIRomero-GómezMPMoreno-RamosFMingoranceJGarcía-RodríguezJCendejas-BuenoEEpidemiology of bloodstream Candida species in a Spanish tertiary care hospital as a guide for implementation of T2MR (T2CANDIDA®) for rapid diagnosis of candidemiaMed Mycol2021594350410.1093/mmy/myaa056Search in Google Scholar
Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006;43:25–31.GareyKWRegeMPaiMPMingoDESudaKJTurpinRSet alTime to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional studyClin Infect Dis200643253110.1086/504810Search in Google Scholar
Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003;3:772–85.EggimannPGarbinoJPittetDManagement of Candida species infections in critically ill patientsLancet Infect Dis200337728510.1016/S1473-3099(03)00831-4Search in Google Scholar
Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161–89.PappasPGRexJHSobelJDFillerSGDismukesWEWalshTJet alGuidelines for treatment of candidiasisClin Infect Dis2004381618910.1086/38079614699449Search in Google Scholar
Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP; National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;5:627–30.TrickWEFridkinSKEdwardsJRHajjehRAGaynesRP; National Nosocomial Infections Surveillance System HospitalsSecular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999Clin Infect Dis200256273010.1086/34230012173140Search in Google Scholar
Tortorano AM, Caspani L, Rigoni AL, Biraghi E, Sicignano A, Viviani MA. Candidosis in the intensive care unit: a 20-year survey. J Hosp Infect 2004;57:8–13.TortoranoAMCaspaniLRigoniALBiraghiESicignanoAVivianiMACandidosis in the intensive care unit: a 20-year surveyJ Hosp Infect20045781310.1016/j.jhin.2004.01.01715142710Search in Google Scholar
Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002;40:1298–302.DiekemaDJMesserSABrueggemannABCoffmanSLDoernGVHerwaldtLAet alEpidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms studyJ Clin Microbiol200240129830210.1128/JCM.40.4.1298-1302.200214038011923348Search in Google Scholar
Hobson RP. The global epidemiology of invasive Candida infections—is the tide turning? J Hosp Infect 2003;55:159– 68;quiz 233.HobsonRPThe global epidemiology of invasive Candida infections—is the tide turning?J Hosp Infect200355159–68quiz 23310.1016/j.jhin.2003.08.01214572481Search in Google Scholar
Davis SL, Vazquez. Anidulafungin: an evidence-based review of its use in invasive fungal infections. Core Evid 2007;2:241–9.DavisSLVazquezAnidulafungin: an evidence-based review of its use in invasive fungal infectionsCore Evid200722419Search in Google Scholar
Hanson KE, Pfeifer CD, Lease ED, Balch AH, Zaas AK, Perfect JR, et al. β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS One 2012;7:e42282.HansonKEPfeiferCDLeaseEDBalchAHZaasAKPerfectJRet alβ-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot studyPLoS One20127e4228210.1371/journal.pone.0042282341284822879929Search in Google Scholar
Ket DH, Azoulay E, Echeverria PM, Vincent JL. Extended prevalence of infection in ICU study (EPIC II) group of investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011;39:665–70.KetDHAzoulayEEcheverriaPMVincentJLExtended prevalence of infection in ICU study (EPIC II) group of investigatorsCandida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med2011396657010.1097/CCM.0b013e318206c1ca21169817Search in Google Scholar
Pfaller MA1, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001;39:3254–9.PfallerMA1DiekemaDJJonesRNSaderHSFluitACHollisRJet alInternational surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazoleravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol2001393254910.1128/JCM.39.9.3254-3259.20018832711526159Search in Google Scholar
Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol 2011;49:665-70.AvniTLeiboviciLPaulMPCR diagnosis of invasive candidiasis: systematic review and meta-analysisJ Clin Microbiol2011496657010.1128/JCM.01602-10304351821106797Search in Google Scholar
Moghnieh R, Kanafani ZA, Kanj SS. Antifungal use in intensive care units: another uncertainty that highlights the need for precision medicine. J Thorac Dis 2016;8:E1672-5.MoghniehRKanafaniZAKanjSSAntifungal use in intensive care units: another uncertainty that highlights the need for precision medicineJ Thorac Dis20168E1672510.21037/jtd.2016.12.97522726728149610Search in Google Scholar
Lamagni TL, Evans BG, Shigematsu M, Johnson EM. Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990-9). Epidemiol Infect 2001;126:397-414.LamagniTLEvansBGShigematsuMJohnsonEMEmerging trends in the epidemiology of invasive mycoses in England and Wales (1990-9)Epidemiol Infect200112639741410.1017/S0950268801005507286970811467797Search in Google Scholar
Flückiger U, Marchetti O, Bille J, Eggimann P, Zimmerli S, Imhof A, et al. Treatment options of invasive fungal infections in adults. Swiss Med Wkly 2006;136:447-63.FlückigerUMarchettiOBilleJEggimannPZimmerliSImhofAet alTreatment options of invasive fungal infections in adultsSwiss Med Wkly200613644763Search in Google Scholar
Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009;48:1695–703.HornDLNeofytosDAnaissieEJFishmanJASteinbachWJOlyaeiAJet alEpidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registryClin Infect Dis200948169570310.1086/59903919441981Search in Google Scholar
Schuster MG, Edwards JE Jr, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008;149:83-90.SchusterMGEdwardsJE JrSobelJDDarouicheROKarchmerAWHadleySet alEmpirical fluconazole versus placebo for intensive care unit patients: a randomized trialAnn Intern Med2008149839010.7326/0003-4819-149-2-200807150-0000418626047Search in Google Scholar
Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Bets R, Barron MA, et al. MSG- 01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care seting. Clin Infect Dis 2014;58:121926.Ostrosky-ZeichnerLShohamSVazquezJReboliABetsRBarronMAet alMSG- 01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setingClin Infect Dis20145812192610.1093/cid/ciu07424550378Search in Google Scholar
Timsit JF, Azoulay E, Schwebel C, Charles PE, Cornet M, Souweine B, et al. Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure: The EMPIRICUS randomized clinical trial. JAMA 2016;316:1555-64.TimsitJFAzoulayESchwebelCCharlesPECornetMSouweineBet alEmpirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure: The EMPIRICUS randomized clinical trialJAMA201631615556410.1001/jama.2016.1465527706483Search in Google Scholar
Sabol K, Gumbo T. Anidulafungin in the treatment of invasive fungal infections. Ther Clin Risk Manag 2008;4:71-8.SabolKGumboTAnidulafungin in the treatment of invasive fungal infectionsTher Clin Risk Manag2008471810.2147/TCRM.S882Search in Google Scholar
Concia E, Azzini AM, Conti M. Epidemiology, incidence and risk factors for invasive candidiasis in high‐risk patients. Drugs 2009;69:5-14.ConciaEAzziniAMContiMEpidemiology, incidence and risk factors for invasive candidiasis in high‐risk patientsDrugs20096951410.2165/11315500-000000000-0000019877728Search in Google Scholar
Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-163.PfallerMADiekemaDJEpidemiology of invasive candidiasis: a persistent public health problemClin Microbiol Rev20072013316310.1128/CMR.00029-06179763717223626Search in Google Scholar
López-Cortés LE, Almirante B, Cuenca-Estrella M, Garnacho-Montero J, Padilla B, Puig-Asensio M, et al. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort. Clin Microbiol Infect 2016;22:733.e1-8.López-CortésLEAlmiranteBCuenca-EstrellaMGarnacho-MonteroJPadillaBPuig-AsensioMet alEmpirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohortClin Microbiol Infect201622733e1-810.1016/j.cmi.2016.05.00827189197Search in Google Scholar
Pfaller MA, Diekema DJ, Rinaldi MG, Barnes R, Hu B, Veselov AV, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5‐year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk difusion testing. J Clin Microbiol 2005;43:5848-5859.PfallerMADiekemaDJRinaldiMGBarnesRHuBVeselovAVet alResults from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5‐year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk difusion testingJ Clin Microbiol2005435848585910.1128/JCM.43.12.5848-5859.2005131720716333066Search in Google Scholar
Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012,54:1110-22.AndesDRSafdarNBaddleyJWPlayfordGReboliACRexJHet alImpact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trialsClin Infect Dis20125411102210.1093/cid/cis02122412055Search in Google Scholar
Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005;43:5425-7.PfallerMABoykenLHollisRJMesserSATendolkarSDiekemaDJIn vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazoleJ Clin Microbiol2005435425710.1128/JCM.43.11.5425-5427.2005128782316272464Search in Google Scholar
Morace G, Borghi E, Iata R, Montagna MT. Anidulafungin, a new echinocandin: in vitro activity. Drugs 2009;69:91-94.MoraceGBorghiEIataRMontagnaMTAnidulafungin, a new echinocandin: in vitro activityDrugs200969919410.2165/11315560-000000000-0000019877740Search in Google Scholar
Diekema DJ, Messer SA, Boyken LB, Hollis RJ, Kroeger J, Tendolkar S, et al. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol 2009;47:3170-7.DiekemaDJMesserSABoykenLBHollisRJKroegerJTendolkarSet alIn vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methodsJ Clin Microbiol2009473170710.1128/JCM.00942-09275693119710283Search in Google Scholar
Cuenca‐Estrella M, Mellado E, Díaz‐Guerra TM, Monzón A, Rodríguez‐Tudela JL. Susceptibility of fluconazole‐resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. J Antimicrob Chemother 2000;46:475-7.Cuenca‐EstrellaMMelladoEDíaz‐GuerraTMMonzónARodríguez‐TudelaJLSusceptibility of fluconazole‐resistant clinical isolates of Candida sppto echinocandin LY303366, itraconazole and amphotericin B. J Antimicrob Chemother200046475710.1093/jac/46.3.47510980178Search in Google Scholar
Gil-Alonso S, Quindós G, Cantón E, Eraso E, Jauregizar N. Killing kinetics of anidulafungin, caspofungin and micafungin against Candida parapsilosis species complex: Evaluation of the fungicidal activity. Rev Iberoam Micol 2019;36(1):24-9.Gil-AlonsoSQuindósGCantónEErasoEJauregizarNKilling kinetics of anidulafungin, caspofungin and micafungin against Candida parapsilosis species complex: Evaluation of the fungicidal activityRev Iberoam Micol201936124910.1016/j.riam.2018.12.00130837186Search in Google Scholar
Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472-82.ReboliACRotsteinCPappasPGChapmanSWKettDHKumarDet alAnidulafungin versus fluconazole for invasive candidiasisN Engl J Med200735624728210.1056/NEJMoa06690617568028Search in Google Scholar
Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006;44:760-3.PfallerMABoykenLHollisRJMesserSATendolkarSDiekemaDJIn vitro susceptibilities of Candida sppto caspofungin: four years of global surveillance. J Clin Microbiol200644760310.1128/JCM.44.3.760-763.2006139315416517851Search in Google Scholar
Ghannoum MA, Chen A, Buhari M, Chandra J, Mukherjee PK, Baxa D, et al. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clin Microbiol Infect 2009;15:274-9.GhannoumMAChenABuhariMChandraJMukherjeePKBaxaDet alDifferential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unitClin Microbiol Infect200915274910.1111/j.1469-0691.2008.02660.x19210699Search in Google Scholar
Jacobson MJ, Piper KE, Nguyen G, Steckelberg JM, Patel R. In vitro activity of anidulafungin against Candida albicans biofilms. Antimicrob Agents Chemother 2008;52:2242-3.JacobsonMJPiperKENguyenGSteckelbergJMPatelRIn vitro activity of anidulafungin against Candida albicans biofilmsAntimicrob Agents Chemother2008522242310.1128/AAC.00211-08241579518391031Search in Google Scholar
Mayr A, Aigner M, Lass-Flörl C. Anidulafungin for the treatment of invasive candidiasis. Clin Microbiol Infect 2011;17:1-12.MayrAAignerMLass-FlörlCAnidulafungin for the treatment of invasive candidiasisClin Microbiol Infect20111711210.1111/j.1469-0691.2010.03448.x21251147Search in Google Scholar
Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 2000;44:1108-11.ErnstEJKlepserMEPfallerMAPostantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformansAntimicrob Agents Chemother20004411081110.1128/AAC.44.4.1108-1111.20008982610722525Search in Google Scholar
Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin‐specific and Candida species‐ related differences. Antimicrob Agents Chemother 2007;51:2257-9.ChamilosGLewisREAlbertNKontoyiannisDPParadoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin‐specific and Candida species‐ related differencesAntimicrob Agents Chemother2007512257910.1128/AAC.00095-07189135817438060Search in Google Scholar
Fleischhacker M, Radecke C, Schulz B, Ruhnke M. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur J Clin Microbiol Infect Dis 2008;27:127-31.FleischhackerMRadeckeCSchulzBRuhnkeMParadoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and Cdubliniensis. Eur J Clin Microbiol Infect Dis2008271273110.1007/s10096-007-0411-418057972Search in Google Scholar
Falcone M, Accarpio F, Venditti M, Vena A, Sibio S, Sammartino P, et al. Septic bilateral pulmonary candidiasis successfully treated with anidulafungin therapy in two patients with peritoneal carcinomatosis. J Antimicrob Chemother 2010;65:2266-7.FalconeMAccarpioFVendittiMVenaASibioSSammartinoPet alSeptic bilateral pulmonary candidiasis successfully treated with anidulafungin therapy in two patients with peritoneal carcinomatosisJ Antimicrob Chemother2010652266710.1093/jac/dkq29720682563Search in Google Scholar
Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft RF, Pope JS, et al. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob Agents Chemother 2009;53:5102-7.CrandonJLBaneviciusMAFangAFCrownoverPHKnauftRFPopeJSet alBronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adultsAntimicrob Agents Chemother2009535102710.1128/AAC.01042-09278633019770284Search in Google Scholar
Petraitis V, Petraitiene R, Hope WW, Meletiadis J, Mickiene D, Hughes JE, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother 2009;53:2382-91.PetraitisVPetraitieneRHopeWWMeletiadisJMickieneDHughesJEet alCombination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysisAntimicrob Agents Chemother20095323829110.1128/AAC.00329-09268722319307368Search in Google Scholar
Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin Infect Dis 2004;38:311-20.MarchettiOBilleJFluckigerUEggimannPRuefCGarbinoJet alEpidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000Clin Infect Dis2004383112010.1086/38063714727199Search in Google Scholar
Marra AR, Camargo LF, Pignatari AC, Sukiennik T, Behar PR, Medeiros EA, et al. Nosocomial bloodstream infections in Brazilian hospitals: analysis of 2,563 cases from a prospective nationwide surveillance study. J Clin Microbiol 2011;49:1866-71.MarraARCamargoLFPignatariACSukiennikTBeharPRMedeirosEAet alNosocomial bloodstream infections in Brazilian hospitals: analysis of 2,563 cases from a prospective nationwide surveillance studyJ Clin Microbiol20114918667110.1128/JCM.00376-11312265321411591Search in Google Scholar
Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17.WisplinghoffHBischoffTTallentSMSeifertHWenzelRPEdmondMBNosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance studyClin Infect Dis2004393091710.1086/42194615306996Search in Google Scholar
Cappelletty DM, Jung R. Anidulafungin and its role in candida infections. Infect Drug Resist 2009;2:51-60.CappellettyDMJungRAnidulafungin and its role in candida infectionsInfect Drug Resist20092516010.2147/IDR.S4796310872921694887Search in Google Scholar
Kett DH, Shorr AF, Reboli AC, Reisman AL, Biswas P, Schlamm HT. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Crit Care 2011;15:R253.KettDHShorrAFReboliACReismanALBiswasPSchlammHTAnidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasisCrit Care201115R25310.1186/cc10514333480422026929Search in Google Scholar
Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006;25:419-25.FalagasMEApostolouKEPappasVDAttributable mortality of candidemia: a systematic review of matched cohort and case-control studiesEur J Clin Microbiol Infect Dis2006254192510.1007/s10096-006-0159-216773391Search in Google Scholar
Colombo AL, Guimarães T, Sukienik T, Pasqualotto AC, Andreotti R, Queiroz-Telles F, et al. Prognostic factors and histor-ical trends in the epidemiology of candidemia in critically ill patients: ananalysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med 2014;40:1489–98.ColomboALGuimarãesTSukienikTPasqualottoACAndreottiRQueiroz-TellesFet alPrognostic factors and histor-ical trends in the epidemiology of candidemia in critically ill patients: ananalysis of five multicenter studies sequentially conducted over a 9-year periodIntensive Care Med20144014899810.1007/s00134-014-3400-y417683125082359Search in Google Scholar
Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41:1232-9.ZaoutisTEArgonJChuJBerlinJAWalshTJFeudtnerCThe epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysisClin Infect Dis2005411232910.1086/49692216206095Search in Google Scholar
Reboli AC, Rotstein C, Kett DH, Maschio M, Cartier S, Chambers R, et al. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients. Pharmacoeconomics 2011;29:705-17.ReboliACRotsteinCKettDHMaschioMCartierSChambersRet alResource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patientsPharmacoeconomics2011297051710.2165/11584810-000000000-0000021591820Search in Google Scholar
Ruhnke M, Paiva JA, Meersseman W, Pachl J, Grigoras I, Sganga G, et al. Anidulafungin for the treatment of candidaemia/ invasive candidiasis in selected critically ill patients. Clin Microbiol Infect 2012;18:680-7.RuhnkeMPaivaJAMeerssemanWPachlJGrigorasISgangaGet alAnidulafungin for the treatment of candidaemia/ invasive candidiasis in selected critically ill patientsClin Microbiol Infect201218680710.1111/j.1469-0691.2012.03784.x351030622404732Search in Google Scholar